| human | Q5 |
| P496 | ORCID iD | 0000-0001-7349-0176 |
| P735 | given name | Ann | Q558067 |
| Ann | Q558067 | ||
| P106 | occupation | researcher | Q1650915 |
| Q35115650 | (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma |
| Q35954408 | A mixed methods approach to developing and evaluating oncology trainee education around minimization of adverse events and improved patient quality and safety. |
| Q41001462 | A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma |
| Q36892621 | A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma |
| Q40168362 | A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). |
| Q102382597 | A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay |
| Q91760487 | AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology |
| Q89777411 | Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes |
| Q36624952 | Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome |
| Q41127479 | An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era |
| Q37125104 | Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma |
| Q90315257 | Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility |
| Q47237352 | Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis |
| Q33958944 | Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. |
| Q26825581 | Biology of double-hit B-cell lymphomas |
| Q90321401 | Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403 |
| Q33393436 | Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma |
| Q95764208 | Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma |
| Q52716122 | Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. |
| Q92665875 | Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma |
| Q58083758 | CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma |
| Q92282088 | Cancer Treatment-Related Infertility: A Critical Review of the Evidence |
| Q90898469 | Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology |
| Q59770468 | Cardiac Presentation of Anaplastic Large-Cell Lymphoma |
| Q40043135 | Case 25-2017. |
| Q43109654 | Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to pat |
| Q36826893 | Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 |
| Q81978998 | Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant |
| Q85063202 | Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation |
| Q34548829 | Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. |
| Q84167962 | Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET |
| Q39665794 | Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database |
| Q34034389 | Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network |
| Q37119439 | Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network |
| Q93261031 | Current considerations in AYA Hodgkin lymphoma |
| Q92215817 | Cutaneous Eruptions from Ibrutinib Resembling EGFR Inhibitor-Induced Dermatologic Adverse Events |
| Q37304122 | Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes |
| Q44588555 | Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma |
| Q87238648 | Diffuse Large B-Cell Lymphoma Version 1.2016 |
| Q64120388 | Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study |
| Q35029924 | Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET |
| Q85207004 | End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma |
| Q94700480 | Enzastaurin |
| Q64120868 | Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders |
| Q34627112 | Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis |
| Q33404317 | Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma |
| Q91752253 | Evidence-Based Minireview: What is the optimal timing of anti-PD-1 antibodies in relapsed classical Hodgkin lymphoma? |
| Q89769393 | Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma |
| Q79467568 | Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma |
| Q92090070 | Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma |
| Q53249325 | Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma. |
| Q39326964 | High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex |
| Q46305110 | High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. |
| Q40464625 | Hospice Use Among Patients With Lymphoma: Impact of Disease Aggressiveness and Curability. |
| Q41725426 | How I treat Burkitt lymphoma in adults |
| Q39437144 | How to Approach a Patient With Limited Stage Hodgkin Lymphoma Who Remains PET Positive at the End of Chemotherapy: Radiation Therapy? |
| Q40071847 | Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy |
| Q92823144 | Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial |
| Q54338742 | Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. |
| Q37474352 | Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. |
| Q41876102 | Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning |
| Q45209213 | Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklist |
| Q24599100 | Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia |
| Q44635336 | Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? |
| Q47563022 | Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma |
| Q53143673 | Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. |
| Q45349740 | Large vessel vasculopathy in Epstein-Barr virus-positive diffuse large B-cell lymphoma |
| Q45174932 | Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients |
| Q37864001 | Long-term complications of lymphoma and its treatment |
| Q30252598 | Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. |
| Q36796554 | Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation |
| Q37817421 | Lymphoma: risk and response after solid organ transplant. |
| Q34102089 | NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas |
| Q92754901 | NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 |
| Q43753478 | NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. |
| Q47607400 | NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. |
| Q40427138 | NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes |
| Q33392920 | Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity |
| Q37552503 | Nodular lymphocyte predominant Hodgkin lymphoma |
| Q85636631 | Non-Hodgkin's Lymphomas, version 3.2012 |
| Q82684094 | Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology |
| Q81144359 | Non-Hodgkin's lymphomas |
| Q84061371 | Non-Hodgkin's lymphomas |
| Q45276579 | Non-Hodgkin's lymphomas, version 1.2013. |
| Q88071273 | Non-Hodgkin's lymphomas, version 2.2014 |
| Q36820885 | Non-Hodgkin's lymphomas, version 4.2014. |
| Q91752017 | Novel agents and immune invasion in Hodgkin lymphoma |
| Q57464309 | Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia |
| Q58415161 | Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma |
| Q45071301 | Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. |
| Q34018599 | Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens |
| Q92518269 | PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation |
| Q38868430 | PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma |
| Q92884621 | PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation |
| Q85941661 | Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes |
| Q42954066 | Phase 1 trial of bortezomib plus R‐CHOP in previously untreated patients with aggressive non‐Hodgkin lymphoma |
| Q34943963 | Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lympho |
| Q33394487 | Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia |
| Q33374692 | Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma |
| Q89081070 | Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL |
| Q79775030 | Post-transplant lymphoproliferative disorders |
| Q82146571 | Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy |
| Q92109856 | Preparing Fellows for Graduation: Perspectives on Career Guidance |
| Q38684561 | Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation |
| Q37247342 | Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders |
| Q83650477 | Primary mediastinal large B-cell lymphoma |
| Q85821231 | Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era |
| Q45960960 | Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. |
| Q64100227 | Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition |
| Q41151021 | Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project |
| Q38376595 | Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation |
| Q33376043 | Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database |
| Q91481521 | Reply to H.J.A. Adams et al |
| Q88771664 | Response-Adapted Therapy in Aggressive Lymphoma: Not Yet Ready for Clinical Care |
| Q53251023 | Richter's transformation of chronic lymphocytic leukemia. |
| Q36036173 | Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant |
| Q89998342 | Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma |
| Q38398550 | Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma |
| Q27851724 | Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma |
| Q98882662 | Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma |
| Q47843221 | Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. |
| Q91274194 | Suicide in European Hodgkin Lymphoma Patients |
| Q95811406 | Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis |
| Q42239270 | Targeting Epstein-Barr virus-associated lymphomas |
| Q62963901 | The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice |
| Q37526352 | The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice |
| Q35155350 | The epidemiology of herpes zoster and its complications in Medicare cancer patients. |
| Q101559961 | The treatment of Burkitt lymphoma in adults |
| Q36498968 | Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501) |
| Q89672653 | Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma |
| Q39335736 | Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database |
| Q92675466 | Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease |
| Q39900275 | Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy |
| Q37138259 | US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. |
| Q36521840 | Update on the therapy of highly aggressive non-Hodgkin's lymphoma |
Search more.